Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, also known as PNB-0408) is a synthetic hexapeptide derived from Angiotensin IV that gained significant attention when research from the University of Washington showed it to be approximately 10 million times more potent than BDNF (brain-derived neurotrophic factor) at driving synaptogenesis — the formation of new synaptic connections between neurons. While BDNF must be introduced directly into brain tissue to show effect at similar concentrations, Dihexa is orally and transdermally active at remarkably low doses. Its potential implications for neuroplasticity, cognitive enhancement, and neurodegenerative disease are significant.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
The structural nature of Dihexa's mechanism — promoting actual synapse formation — suggests effects may persist beyond the active compound's presence. Community experience reports that some cognitive improvements from a Dihexa cycle persist for weeks to months after discontinuation, consistent with durable synaptic changes. This is speculative in the absence of human data, but mechanistically plausible.
How Does Dihexa Work?
Dihexa works through the HGF (Hepatocyte Growth Factor) / c-Met receptor pathway — a distinct mechanism from most other nootropic peptides. HGF/c-Met signalling drives neuronal survival, migration, axonal growth, and synaptogenesis. Dihexa appears to act as an HGF mimetic or potentiator: it binds to a site on HGF's receptor-binding domain and amplifies signalling through c-Met, stimulating downstream cascade activation that drives synapse formation.
The 10 million times more potent comparison to BDNF should be interpreted carefully: this is specifically for synaptogenesis in hippocampal slice cultures under controlled conditions — it does not mean Dihexa has generally 10M× broader cognitive effects than BDNF. What it does indicate is that Dihexa requires dramatically lower concentrations to drive synaptic formation in that context, and that it is active at doses where most compounds would have no detectable effect.
Cognitive Effects: What Users Report
Dihexa has a notably different character than typical stimulant-class nootropics. Rather than producing immediate focus or energy, its effects — when experienced — are described as a gradual but profound improvement in cognitive clarity, verbal fluency, associative thinking, and problem-solving depth over days to weeks. Community reports frequently describe the sensation as "thinking more clearly" rather than "thinking faster" — consistent with the hypothesised mechanism of improved synaptic connectivity rather than neurotransmitter modulation.
The slower onset (days to full effect) distinguishes Dihexa from Semax or Selank, which produce more immediate effects. This is consistent with a mechanism driven by structural synaptogenesis rather than neurochemical modulation. Users in complex cognitive work (research, writing, programming) report it among the most impactful nootropic compounds tried.
Dosing and Routes of Administration
Dihexa is typically used at very low doses: 1–10 mg transdermally (in a DMSO or ethanol carrier) applied to the inner wrist, or 10–20 mg orally. Subcutaneous injection at 1–5 mg is also used but less common. The extremely high potency means low doses are appropriate and titrating up carefully is warranted. Cycle lengths of 4–8 weeks with breaks are standard — there are reports of diminishing effects with very long continuous use, consistent with receptor adaptation.
Transdermal delivery through the wrist is a common administration route because it is non-invasive and Dihexa's lipophilicity supports dermal absorption. However, absorption efficiency via this route is lower and more variable than injection, and DMSO carriers can cause local skin irritation.
Safety Considerations and Open Questions
Dihexa is among the least-studied peptides in active community research use. No published human clinical data exists; virtually all preclinical data comes from Washington University's Joseph Harding lab. The HGF/c-Met pathway that Dihexa activates has oncogenic potential — c-Met amplification is observed in several cancers, and HGF signalling promotes tumour angiogenesis and invasiveness in existing malignancies. This raises a theoretical concern that Dihexa use could accelerate growth in pre-existing cancers, though no evidence of tumour promotion in healthy animal subjects exists in the published literature.
This is not a reason to assume Dihexa is carcinogenic, but it is a mechanism-based reason for caution: individuals with known active cancer or high cancer risk should consult an oncologist before use. The general risk assessment for otherwise-healthy individuals remains unclear due to the limited data set.
Dihexa Research Profile
| Parameter | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Primary mechanism | HGF/c-Met pathway; synaptogenesis | — | — | — |
| Typical dose | 1–10 mg (transdermal) / 10–20 mg (oral) | — | — | — |
| Onset | Days to weeks (structural mechanism) | — | — | — |
| Cycle length | 4–8 weeks with breaks | — | — | — |
| Human trial data | None published | — | — | — |
| Primary concern | Theoretical oncogenic risk (c-Met pathway) | — | — | — |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
For synaptogenesis specifically, Dihexa has the most dramatic potency data in preclinical research — the HGF/c-Met mechanism at its effective concentrations is unmatched. However, "strongest nootropic" depends entirely on the desired effect. Semax and NA-Semax produce more immediate, day-of cognitive enhancement via BDNF and monoamine mechanisms. Dihexa's effects are more structural and long-latency. The comparison depends on what kind of cognitive improvement you are researching.
The structural nature of Dihexa's mechanism — promoting actual synapse formation — suggests effects may persist beyond the active compound's presence. Community experience reports that some cognitive improvements from a Dihexa cycle persist for weeks to months after discontinuation, consistent with durable synaptic changes. This is speculative in the absence of human data, but mechanistically plausible.
No evidence of carcinogenesis in healthy animal subjects has been published. The concern is theoretical: c-Met activation can support existing cancer cell growth and invasion. In healthy subjects without pre-existing cancer, the current evidence does not indicate carcinogenic risk from Dihexa. However, the evidence base is limited and the mechanism warrants awareness. Individuals with personal or family cancer history should consider this uncertainty carefully.
Dihexa is available from some research peptide vendors as a research chemical. Due to its limited availability and high potency at low doses, it is less commonly stocked than BPC-157, Semax, or GH peptides. Verify purity via HPLC COA from any vendor given that dosing errors at this potency scale are more consequential.